Biotech Stocks Rally Broadly Monday, With Arcutis Up About 12% And Anavex Lagging
94 of 112 major biotech names were higher at 1:12 p.m. ET Monday, with the group's median gain ahead of the S&P 500.
Biotech shares rose broadly in Monday trading: 94 of 112 major names were higher, 17 lower and 1 unchanged as of 1:12 p.m. ET, with the group's median gain of about 2.0% against about 0.5% for the S&P 500.
Who led and who lagged
Arcutis Biotherapeutics, a dermatology drugmaker, led the group at about 12% in Monday trading as of 1:12 p.m. ET, adding about $445 million in market value. Its market value stood near $4.1 billion after the intraday jump, on pace for its biggest one-day gain since October 2025.
Zenas BioPharma rose about 10%, adding about $169 million, and Xeris Biopharma Holdings also rose about 10%, adding about $191 million.
Anavex Life Sciences was the biggest decliner, down about 8%. ImmunityBio fell about 6% and Novavax about 4%.
The group's median gain put biotech 1.5 percentage points ahead of the S&P 500 at that point in Monday's session. The group is made up of drug developers, many still testing their first medicines and not yet profitable.
Arcutis's recent record
Arcutis was down about 1% this year through Friday's close, against a gain of about 12% for the S&P 500, but had risen 10% over the previous month.
Its second-quarter results showed Zoryve revenue of $129.9 million, up 59% from a year earlier and 23% from the first quarter. The company raised full-year net product sales guidance to $525 million to $540 million.
The release also reported $12.6 million of operating cash flow for the quarter and an FDA target decision date of February 23, 2027, for Zoryve cream 0.05% in infants with atopic dermatitis. Topline results from a mid-stage vitiligo trial are anticipated in the fourth quarter of 2026.
What to watch
Travere Therapeutics reports results Thursday, followed by Kiniksa Pharmaceuticals International on October 26 and Ionis Pharmaceuticals on October 27.
Arcutis's own vitiligo readout, due in the fourth quarter of 2026, is the next company-specific event in its release.